STOCK TITAN

Health Catalyst (HCAT) insider sale notice: 15,726 shares via Morgan Stanley on 03/02/2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Health Catalyst, Inc. reported a Form 144 notice for the proposed sale of 15,726 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 03/02/2026.

The filing also discloses recent insider sales by Kevin Freeman: 16,401 shares sold on 12/01/2025 for $47,566.18 and 6,614 shares sold on 02/26/2026 for $11,559.95.

Positive

  • None.

Negative

  • None.

Insights

Form 144 shows a planned brokered sale and recent insider dispositions by Kevin Freeman.

The filing lists a proposed sale of 15,726 shares through Morgan Stanley Smith Barney LLC on 03/02/2026. This is presented as a notice of intent to sell under the securities rules; timing and execution depend on broker and regulatory conditions.

Past transactions recorded include sales of 16,401 shares on 12/01/2025 for $47,566.18 and 6,614 shares on 02/26/2026 for $11,559.95. Subsequent filings will show executed sales and final proceeds.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Health Catalyst's Form 144 disclose about proposed sales?

It discloses a proposed sale of 15,726 shares to be executed through Morgan Stanley Smith Barney on 03/02/2026. The notice indicates the intention to sell common stock under the securities rules; execution details depend on broker and clearance.

Who is the insider named and what recent sales are reported for HCAT?

Kevin Freeman is named as the reporting person with recent sales of 16,401 shares on 12/01/2025 for $47,566.18 and 6,614 shares on 02/26/2026 for $11,559.95. These are reported as past transactions.

Through which broker will the proposed HCAT sale occur?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC, listed with an address at 1 New York Plaza, 38th Floor, New York, NY. The filing names the broker as the intermediary for the proposed transaction on 03/02/2026.

Are the proceeds from the proposed 15,726-share sale disclosed in the Form 144?

The excerpt does not state proceeds for the 15,726-share proposed sale. The filing lists the share quantity and broker for 03/02/2026; proceeds or prices for that proposed sale are not provided in the provided excerpt.

Do the recent insider sales appear in the filing as executed transactions?

Yes, two executed sales by Kevin Freeman are reported: 16,401 shares on 12/01/2025 for $47,566.18 and 6,614 shares on 02/26/2026 for $11,559.95. These are listed under securities sold during the past three months.
Health Catalyst

NASDAQ:HCAT

View HCAT Stock Overview

HCAT Rankings

HCAT Latest News

HCAT Latest SEC Filings

HCAT Stock Data

137.93M
63.26M
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States
SOUTH JORDAN